Newsletter registration

Austria.
Where Great Emphasis is Put on Research.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • 2. Mittelstandsforum Nordrhein-Westfalen

    28.06.2017, Düsseldorf, Germany

  • Meet us at „Russia-Europe: Cooperation without frontiers”

    29. – 30.06.2017, Moscow, Russia

Austria Map

Find the perfect location for your company

Austria is well known for its social stability and excellent labor relations where strikes are measured only in seconds. As a global player, reliable deliveries are a top priority for us.

Opel Austria

Logo
More testimonials

news from the business location Austria

Austria on the verge of entering the top ranks of innovators: European Innovation Scoreboard 2017 shows leap to 7th place

“Austria is on the verge of entering the top ranks in Europe with respect to innovation. In only two years, we improved from 11th to 7th place, which is the second best results every achieved in the history of the European Innovation Scorecard. This shows that we are on the path to success, and that our measures and projects such as increasing R&D investments or our open innovation strategy are beginning to have an impact”, says Harald Mahrer, Federal Minister of Science, Research and Economy, commenting on the European Innovation Scorecard 2017 published by the European Commission.

Research premium: added impetus to Research Location Austria

One positive signal for research companies based in Austria occurred in 2016: the increase in the research premium from 10% to 12% was already an important measure designed to strengthen the domestic research landscape.

More news All blog posts